<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<pubmed-document>
<record>
<header>
<identifier>1004677</identifier>
<setSpec>0028-3851</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:author>DÃ­az Solano, C</dc:author>
<dc:description xml:lang="en">Thirty out patients were selected in a psychiatric hospital among those presenting insomnia, anxiety, psychomotor retardation, loss of drive and anxiety with somatic manifestations. Amytryptyline was administered in 25 mg tablets, one to four times a day, for twelve weeks. Results were satisfactory as observed from the second week; side effects were minimal. We can conclude that amytryptyline is of great effectiveness in the treatment of the neurotic illnesses most commonly observed in clinical practice.</dc:description>
<dc:type>English Abstract</dc:type>
<dc:language>es</dc:language>
<dc:date>1976 </dc:date>
<dc:title xml:lang="es">La amitriptilina en el tratamiento de la ansiedad y el insomnnio, y como tranquilizante</dc:title>
<dc:title xml:lang="en">[Amitriptyline in the treatment of anxiety and insomnia anal as a tranquilizer].</dc:title>
<dc:publisher>Neurologia, neurocirugia, psiquiatria</dc:publisher>
</metadata>
</record>
</pubmed-document>
